Cannabis dispensary chain MedMen seeks to become the "Whole Foods of Pot Shops." Will the company succeed or is it stretched too thin? Read More

Cannabis player Cronos Group is flush with cash, after tobacco giant Altria bought a huge stake in the firm. Does Cronos deserve the hype? Read More

This cannabis infrastructure stock is generating interest among investors who seek a quick killing in the pot market. But could this penny stock kill your portfolio instead? Read More

Small-cap marijuana plays are captivating investors, especially fast-rising penny stocks like Supreme Cannabis. Will this company thrive or crash in 2019? Read More

This clinical stage marijuana biotech is garnering eager investor interest. Is the company poised for greatness or disappointment? Read More

An examination of Therapix Biosciences, its rivals, and a prediction for this micro-cap biotech stock in 2019. Will Therapix prove a winner or loser in the race to develop cannabis-based drugs? Read More

Our review of clinical-stage medical cannabis companies continues, with a fledgling biotech that's generating especially keen interest on Wall Street. Is Cara a future bonanza... or short-term fad? Read More

We spotlight Intec Pharma, its rivals, and whether the stock is overpriced or underpriced. Is this Israel-based biotech on the verge of launching blockbuster new drugs? Read More

An examination of this popular biotech stock, its rivals, whether it's overpriced or underpriced, and a prediction for its prospects in 2019. Read More

Zynerba Pharmaceuticals is a fledgling, small-cap maker of cannabis-based drugs. The stock has attracted considerable media interest, but is it too risky? We sift through the hype to examine the fundamentals. Read More